Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia
Study Comparing Bioavailability of Oral Formulations of Vabicaserin
The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.
- Trial name
- NCT00541996
- Testing
- vabicaserin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Validation of a Tool for the Dimensional Assessment of Apathy in a Population Suffering From Schizophrenia.
Schizophrenia affects about 1% of the world's population. According to the WHO, it was one of the ten most worrying pathologies of the twenty-first century.
- Trial name
- HANDI-AS1 (NCT03801551)
- Testing
- Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
- Where
- 2 sites in France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier de Niort
Treatment-resistant Schizophrenia
Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study.
This exploratory study aims to evaluate the preliminary efficacy and safety of temporal interference (TI) stimulation in patients with treatment-resistant schizophrenia (TRS).
- Trial name
- NCT07773831
- Testing
- Temporal Interference Stimulation
- Volunteers
- 20 people
- Sponsor
- Zhimin Wang
Cannabis, Psychotic Disorders
Cannabinoids, Neural Synchrony, and Information Processing
The study examines the effects of delta-9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient of cannabis, on neural synchrony. Neural synchrony is studied using electroencephalography (EEG).
- Trial name
- THC-Gamma (NCT00708994)
- Testing
- THC
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia, Healthy (Controls)
Exploring the Genetics of Schizophrenia in Manitoba
Schizophrenia is a serious mental illness that affects about 1 in 100 Canadians, shortens life expectancy, and places a large burden on individuals, families, and the healthcare system.
- Trial name
- GENES-MB (NCT07656870)
- Where
- Canada
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Hallucinations, Auditory, Psychosis
Improving Hallucinations by Targeting the rSTS With tES
Hallucinations are a core diagnostic feature of psychotic disorders. They involve different sensory modalities, including auditory, visual, olfactory, tactile, and gustatory hallucinations, among others.
- Trial name
- NCT05165654
- Testing
- Transcranial Electrical Stimulation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Beth Israel Deaconess Medical Center
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Schizophrenia, Negative Symptoms
Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia
Negative symptoms in schizophrenia present a challenge to the clinician owing to their poorer response to conventional treatment with antipsychotics.
- Trial name
- RIS-CIT-SCH (NCT00893256)
- Testing
- Risperidone, Citalopram
- Where
- India
- Volunteers
- 48 people
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
Healthy, Schizophrenia
Eye Blink Response in Healthy Volunteers and Adults With Schizophrenia
The purpose of this study is to explore how the brain works during particular memory tasks in people with schizophrenia and healthy volunteers.
- Trial name
- NCT00001920
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alcohol Dependence, Bipolar Disorder
Treatment of Alcohol Dependence and Comorbid Bipolar Disorder
The study will determine if individuals with co-occurring bipolar disorder and alcohol dependence report reduced alcohol consumption, improvement in mood symptoms, and cognitive performance if treated with lamotrigine plus their…
- Conditions
- Alcohol Dependence, Bipolar Disorder, Depression, Mania
- Trial name
- NCT01015586
- Testing
- Lamotrigine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medical University of South Carolina
Schizophrenia and Disorders With Psychotic Features
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist…
- Trial name
- NCT00748566
- Testing
- Ziprasidone HCL (oral)
- Where
- 32 sites in Canada
- Volunteers
- 172 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Disease, Mental Disorder
Reducing Cardiovascular Risk in Adults With Serious Mental Illness
This purpose of this study is to adapt, implement and test the ability of a sophisticated point-of-care electronic health record-based clinical decision support that identifies and prioritizes all available evidence-based…
- Conditions
- Chronic Disease, Mental Disorder, Health Behavior, Bipolar Disorder
- Trial name
- SMIWizard (NCT02451670)
- Testing
- Prioritized Clinical Decision Support
- Where
- 3 sites in United States
- Volunteers
- 10,347 people
- Sponsor
- HealthPartners Institute
Prodromal Symptoms, Prodromal Stage
HOPE TEAM - Clinical High Risk Group CBSST
Community-based treatments for adolescents at risk for psychosis are not widely available, nor are there established, gold-standard psychosocial group interventions for this population.
- Conditions
- Prodromal Symptoms, Prodromal Stage, Prodromal States, Psychosis
- Trial name
- NCT03738046
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Sponsor
- University of Pittsburgh
Alcohol Use Disorder, Alcohol Abuse/Dependence
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism
- Trial name
- DUALPSYCHIATRY (NCT06939088)
- Testing
- Tirzepatide
- Where
- 2 sites in Denmark
- Volunteers
- 108 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Schizophrenia
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
- Trial name
- NCT01879722
- Testing
- TAK-063
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Takeda
Schizophrenia
The Effect of Psychoeducation on Healthy Lifestyle Behaviors in Individuals With Schizophrenia
Definition: Schizophrenia is a chronic mental disorder that causes drastic changes in life quality and life functions, characterized by behavioural, cognitive and affective state deterioration.
- Trial name
- NCT05259748
- Testing
- Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors
- Where
- Turkey (Türkiye)
- Volunteers
- 82 people
- Sponsor
- Hatay Training and Research Hospital
Schizophrenia
Single Ascending Dose Study of RBP-7000
The purpose of this study was to assess the safety and tolerability of injections of RBP-7000 in subjects with stable schizophrenia
- Trial name
- NCT02768649
- Testing
- RBP-7000, risperidone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Indivior Inc.
Schizophrenia, Bipolar I Disorder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
This study is an open label, sequential-group, two site, multiple dose escalating study of sublingual administered asenapine in a pediatric population with schizophrenia or bipolar I disorder; in one study cohort (3a)…
- Trial name
- NCT01206517
- Testing
- Asenapine 2.5 mg, Asenapine 5 mg, Asenapine 10 mg
- Volunteers
- 30 people
- Sponsor
- Organon and Co
Schizophrenia
Treatment of Social Cognition in Schizophrenia Trial
This study is a multi-site, prospective, parallel arm, double-blind, randomized, controlled clinical trial to assess the efficacy of an experimental software program targeting social cognitive abilities versus a computer-based…
- Trial name
- TRuSST (NCT02246426)
- Testing
- Computerized plasticity-based adaptive cognitive training, Commercially available computerized training
- Where
- 4 sites in United States
- Volunteers
- 149 people
- Sponsor
- Posit Science Corporation
Schizophrenia
The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism
Investigators plan to explore whether Omega-3 fatty acid have effect on the violent behavior of the schizophrenia patients. Investigators will use PET to explore the influence on serotonin function of the brain to understand the…
- Trial name
- NCT02552758
- Testing
- omega-3 fatty acid, positron emission tomography (PET)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Mental Health Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.